Covid-19 Research at UH
University Hospitals has a proud history of leading the way through innovation and research. As we face the unknown with COVID-19, it is inspiring that UH and the biomedical industry is coming together and assembling a variety of novel and innovative ideas to seek solutions to prevent, treat, and cure COVID-19.
UH COVID-19 Research Projects
- Activation of First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
Dr. Frank Jacono, a University Hospitals Pulmonary and Critical Care Physician, teamed up with Athersys, Inc. to activate UHCMC as the first clinical site for the MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA) trial. University Hospitals has completed trial start-up activities enabling commencement of patient screening and enrollment in this important randomized, double-blind, placebo-controlled study.
- Diaphragm Pacing System Used to Help COVID Patients | Dr. Raymond Onders
Dr. Onders, a surgeon at University Hospitals for the past three decades, and his team of researchers developed a diaphragm pacing system (DPS), which improves the functionality of the diaphragm in patients using ventilators. As a result, the number of days patients use ventilators is reduced, and allowing patients to breathe on their own again. Over the years, this technology has helped patients suffering from spinal cord injury, severe neurologic disorders, post-surgical patients, and most recently, in the medical community’s response to COVID-19.
- Clinical Trial with Novel Anti-Cancer Agent Used for Patients with COVID-19+ Cancer Patients | Dr. Afhin Dowlati
UH currently has an open clinical trial enrolling advanced cancer patients without COVID19. This novel anti-cancer agent inhibits SUMOYLATION. In our current phase I trial with this agent (ongoing) substantial pharmacodynamics effects on the anti-viral response mechanism has been seen. Furthermore preclinical evidence demonstrates anti-viral activity. We are of one of only 6 sites in the world that has access to this drug. TAKEDA Oncology amended their phase I trial to allow patients with advanced cancer and positive for COVID-19 to enroll in the anti-cancer agent trial and look at the endpoints common for COVID19 trials.
- UH Begins a Research Study with ARMS-I Throat Spray to Prevent COVID Transmission | Dr. Robert Salata
On April 2, 2020, UH launched a new clinical trial involving the administration of an investigational drug delivered by simple oral spray, ARMS-I, to our clinical staff who are directly caring for patients. The trial is designed to assess whether the drug helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of health care providers who have tested positive for the virus. Previous studies suggested the active drug is effective in reducing viral infections from influenza and other seasonal viruses.
- UH Among First in the Nation to Test Investigational AntiViral Drug Remdesivir in COVID Patients | Dr. Grace McComsey
University Hospitals has secured two clinical trials that will provide the investigational antiviral drug remdesivir to hospitalized adults with a pneumonia due to the novel coronavirus. One trial will focus on COVID-19 patients with moderate illness. The second will focus on patients with more severe illness who may require care in the intensive care unit (ICU). Remdesivir is designed to interfere with an enzyme that reproduces viral genetic material.
- Harrington Discover Institute: Transatlantic Call for Proposals for New COVID Treatments
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, issued a transatlantic call for proposals for new treatments to support the global fight against novel Coronavirus and potential future pandemic events. Harrington Discovery Institute (HDI) will provide successful applicants with grant funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution.